Abstract
A comparative study of a new tumour marker, CA242, and CA19-9 was conducted with special reference to their diagnostic usefulness in pancreatic cancer. CA242 showed sensitivity similar to that of CA19-9 for overall cases and early cases (stage I tumour) of pancreatic cancer. For other malignancies, the positive rates of CA242 were lower than those of CA19-9 except for colorectal cancer. An important characteristics of CA242 was that it was only slightly and infrequently elevated in the sera of patients with benign diseases such as chronic pancreatitis, chronic hepatitis and liver cirrhosis. This characteristic was more apparent in the patients with benign obstructive jaundice, indicating that the serum level of this marker was scarcely affected by cholestasis. Using cut-off levels corresponding to a 90% specificity, the clinical results obtained with CA242 in the diagnosis of pancreatic cancer were similar to those obtained with CA19-9, except that CA19-9 was falsely negative in some patients with early-stage pancreatic cancer. These findings suggest the usefulness of this marker for screening pancreatic cancer in patients on their first hospital visit. However, CA242 was found to be influenced by the Lewis blood group system. This unfavourable result is attributed to the C241 catcher antibody of this assay system, which has almost the same epitope specificity as the C50 and the NS19-9 monoclonal antibodies. In conclusion, CA242 is superior to CA19-9 in diagnosing pancreatic cancer by virtue of its higher specificity.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kawa, S., Tokoo, M., Hasebe, O. et al. Comparative study of CA242 and CA19-9 for the diagnosis of pancreatic cancer. Br J Cancer 70, 481–486 (1994). https://doi.org/10.1038/bjc.1994.331
Issue Date:
DOI: https://doi.org/10.1038/bjc.1994.331
This article is cited by
-
Diagnostic value of serum carbohydrate antigen 19-9 in pancreatic cancer: a meta-analysis
Tumor Biology (2014)
-
CA19-9 and CA242 as tumor markers for the diagnosis of pancreatic cancer: a meta-analysis
Clinical and Experimental Medicine (2014)
-
Detection of serological biomarkers by proximity extension assay for detection of colorectal neoplasias in symptomatic individuals
Journal of Translational Medicine (2013)
-
“Mass-forming” pancreatitis masquerades as pancreatic carcinoma
International journal of pancreatology (1996)